MILANO VINCENT 4

What Happened

• Vincent Milano, a non-employee director of BioCryst Pharmaceuticals, was granted two awards on 2026-06-11: 15,294 restricted stock units (RSUs) and 33,540 stock-option type awards (reported as a derivative). Both grants show $0 reported acquisition value in the Form 4 filing. These are awards (not purchases or sales) and do not represent an immediate cash investment or sale.

Key Details

• Transaction date: 2026-06-11; Form 4 filed 2026-06-15 (filed within the standard two business-day window).
• RSUs: 15,294 units granted; per footnote, RSUs vest on the first anniversary of the grant.
• Options/derivative: 33,540 option-type awards granted per the director compensation policy (footnote indicates automatic non-employee director stock option grant).
• Reported acquisition price/value: $0 (as reported on the filing for these award entries).
• Shares owned after transaction: not specified in the provided filing excerpt.
• Footnotes: F1 = automatic non-employee director RSU grant; F2 = automatic non-employee director stock option grant under the Director Compensation Policy.

Context

• These awards are routine, automatic director compensation—common for non-employee board members—and do not necessarily signal a personal market view. The RSUs vest in one year, meaning Milano will receive shares only if vesting conditions are met at that time. The options are a derivative grant; the Form 4 does not show exercise or sale activity here.